

PATIENT NAME : AMIT ASHISH

REF. DOCTOR : SELF

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE****XRAY-CHEST**

IMPRESSION NO ABNORMALITY DETECTED

**TMT OR ECHO**

TMT OR ECHO GOOD LV SYSTOLIC FUNCTION AT REST. NO RWMA  
LVEF 60 %  
ALL VALVES STRUCTURALLY NORMAL.  
NO EVIDENCE OF PE/CLOT/VEGETATION.

**ECG**

ECG WITHIN NORMAL LIMITS

**MEDICAL HISTORY**

RELEVANT PRESENT HISTORY HYPERTENSION 6 MONTHS AGO

RELEVANT PAST HISTORY NOT SIGNIFICANT

RELEVANT PERSONAL HISTORY NOT SIGNIFICANT

RELEVANT FAMILY HISTORY HYPERTENSION, DIABETES

HISTORY OF MEDICATIONS NOT SIGNIFICANT

**ANTHROPOMETRIC DATA & BMI**

HEIGHT IN METERS	1.68	mts
WEIGHT IN KGS.	87	Kgs
BMI	31	kg/sqmts

BMI & Weight Status as follows  
Below 18.5: Underweight  
18.5 - 24.9: Normal  
25.0 - 29.9: Overweight  
30.0 and Above: Obese

**GENERAL EXAMINATION**

MENTAL / EMOTIONAL STATE NORMAL

PHYSICAL ATTITUDE NORMAL

GENERAL APPEARANCE / NUTRITIONAL STATUS OBESE

BUILT / SKELETAL FRAMEWORK AVERAGE


FACIAL APPEARANCE NORMAL

SKIN NORMAL

UPPER LIMB NORMAL

LOWER LIMB NORMAL

NECK NORMAL



Dr. J N Shukla ,MBBS, AFIH  
Consultant Physician

Page 1 Of 21



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011697304


PATIENT NAME : AMIT ASHISH

REF. DOCTOR : SELF

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER		
THYROID GLAND	NOT ENLARGED		
CAROTID PULSATION	NORMAL		
TEMPERATURE	NORMAL		
PULSE	66/MIN REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT		
RESPIRATORY RATE	NORMAL		
<b>CARDIOVASCULAR SYSTEM</b>			
BP	140/94 MM HG (SUPINE)		mm/Hg
PERICARDIUM	NORMAL		
APEX BEAT	NORMAL		
HEART SOUNDS	S1, S2 HEARD NORMALLY		
MURMURS	ABSENT		
<b>RESPIRATORY SYSTEM</b>			
SIZE AND SHAPE OF CHEST	NORMAL		
MOVEMENTS OF CHEST	SYMMETRICAL		
BREATH SOUNDS INTENSITY	NORMAL		
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)		
ADDED SOUNDS	ABSENT		
<b>PER ABDOMEN</b>			
APPEARANCE	NORMAL		
VENOUS PROMINENCE	ABSENT		
LIVER	NOT PALPABLE		
SPLEEN	NOT PALPABLE		
HERNIA	ABSENT		
<b>CENTRAL NERVOUS SYSTEM</b>			
HIGHER FUNCTIONS	NORMAL		
CRANIAL NERVES	NORMAL		
CEREBELLAR FUNCTIONS	NORMAL		
SENSORY SYSTEM	NORMAL		
MOTOR SYSTEM	NORMAL		
REFLEXES	NORMAL		



Dr. J N Shukla ,MBBS, AFIH  
Consultant Physician

Page 2 Of 21



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011697304

**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**MUSCULOSKELETAL SYSTEM**

SPINE NORMAL  
 JOINTS NORMAL

**BASIC EYE EXAMINATION**

CONJUNCTIVA NORMAL  
 EYELIDS NORMAL  
 EYE MOVEMENTS NORMAL  
 CORNEA NORMAL  
 DISTANT VISION RIGHT EYE WITHOUT GLASSES REDUCE VISUAL ACUITY (6/9)  
 DISTANT VISION LEFT EYE WITHOUT GLASSES REDUCE VISUAL ACUITY (6/9)  
 NEAR VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT (N6)  
 NEAR VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT (N6)  
 COLOUR VISION NORMAL (17/17)

**BASIC ENT EXAMINATION**


EXTERNAL EAR CANAL NORMAL  
 TYMPANIC MEMBRANE NORMAL  
 NOSE NO ABNORMALITY DETECTED  
 SINUSES NORMAL  
 THROAT NO ABNORMALITY DETECTED  
 TONSILS NOT ENLARGED

**BASIC DENTAL EXAMINATION**

TEETH NORMAL  
 GUMS HEALTHY

**SUMMARY**

RELEVANT HISTORY NOT SIGNIFICANT  
 RELEVANT GP EXAMINATION FINDINGS RAISED BP (140/94)  
 RELEVANT LAB INVESTIGATIONS LOW PLATELET COUNT (136)  
 RAISED LDL (101)  
 RAISED SGOT (62)  
 RAISED SGPT (117)  
 RAISED TSH (4.750)  
 RELEVANT NON PATHOLOGY DIAGNOSTICS USG-MILD FATTY LIVER



**Dr. J N Shukla ,MBBS, AFIH**  
**Consultant Physician**



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
 Mumbai, 400062  
 MAHARASHTRA, INDIA  
 Tel : 9111591115, Fax :  
 CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**

PATIENT NAME : AMIT ASHISH

REF. DOCTOR : SELF

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25


Test Report Status **Final**

Results

Biological Reference Interval Units

REMARKS / RECOMMENDATIONS

RAISED TSH,LOW PLATELET COUNT,RAISED SGOT/SGPT  
 MONITOR BP/TSH PERIODICALLY  
 FOLLOW UP WITH PHYSICIAN FOR ALTERD LFT/FATTY LIVER.



Dr. J N Shukla ,MBBS, AFIH  
 Consultant Physician

Page 4 Of 21



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
 Mumbai, 400062  
 MAHARASHTRA, INDIA  
 Tel : 9111591115, Fax :  
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011697304

**PATIENT NAME : AMIT ASHISH** **REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Units
--------------------	-------	---------	-------

**MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE**

**ULTRASOUND ABDOMEN**

**ULTRASOUND ABDOMEN**

-MILD FATTY LIVER.

**Interpretation(s)**

MEDICAL HISTORY \*\*\*\*\*  
 THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.  
 \*\*\*\*\*

**Dr. J N Shukla ,MBBS, AFIH**  
**Consultant Physician**



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
 Mumbai, 400062  
 MAHARASHTRA, INDIA  
 Tel : 9111591115, Fax :  
 CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**



PATIENT NAME : AMIT ASHISH

REF. DOCTOR : SELF

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## HAEMATOLOGY - CBC

## MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

## BLOOD COUNTS, EDTA WHOLE BLOOD

HEMOGLOBIN (HB)	15.1	13.0 - 17.0	g/dL
METHOD : PHOTOMETRIC MEASUREMENT			
RED BLOOD CELL (RBC) COUNT	4.96	4.5 - 5.5	mil/ $\mu$ L
METHOD : COULTER PRINCIPLE			
WHITE BLOOD CELL (WBC) COUNT	6.80	4.0 - 10.0	thou/ $\mu$ L
METHOD : COULTER PRINCIPLE			
PLATELET COUNT	<b>136 Low</b>	150 - 410	thou/ $\mu$ L
METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY			

## RBC AND PLATELET INDICES

HEMATOCRIT (PCV)	44.3	40.0 - 50.0	%
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV)	89.3	83.0 - 101.0	fL
METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	30.5	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	34.2	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	14.0	11.6 - 14.0	%
METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM			
MENTZER INDEX	18.0		
MEAN PLATELET VOLUME (MPV)	<b>13.1 High</b>	6.8 - 10.9	fL
METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM			

## WBC DIFFERENTIAL COUNT

NEUTROPHILS	51	40 - 80	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY			
LYMPHOCYTES	40	20 - 40	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY			
MONOCYTES	6	2.0 - 10.0	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY			
EOSINOPHILS	3	1.0 - 6.0	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY			

Dr. Reena Mittal, MD  
Senior Consultant  
Hematopathologist

Dr. Sushant Chikane  
Consultant Pathologist

Page 6 Of 21



View Details



View Report

## PERFORMED AT :

SRL Ltd  
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011697304



**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
BASOPHILS		0	0 - 1	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY				
ABSOLUTE NEUTROPHIL COUNT		3.50	2.0 - 7.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		2.70	1.0 - 3.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.41	0.2 - 1.0	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.20	0.02 - 0.50	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		<b>0 Low</b>	0.02 - 0.10	thou/ $\mu$ L
METHOD : CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		1.3		
METHOD : CALCULATED				
<b>MORPHOLOGY</b>				
RBC		PREDOMINANTLY NORMOCYTC NORMOCHROMIC		
METHOD : MICROSCOPIC EXAMINATION				
WBC		NORMAL MORPHOLOGY		
METHOD : MICROSCOPIC EXAMINATION				
PLATELETS		MILDLY REDUCED IN SMEAR, WITH GIANT AND LARGE PLATELETS ARE SEEN		
METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY				

**Interpretation(s)**

BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.  
 RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.  
 WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.  
 (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504  
 This ratio element is a calculated parameter and out of NABL scope.

**Dr. Reena Mittal, MD**  
Senior Consultant  
Hematopathologist

**Dr. Sushant Chikane**  
Consultant Pathologist



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**



MC-2010

PATIENT NAME : AMIT ASHISH

REF. DOCTOR : SELF

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## HAEMATOLOGY

## MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

## ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD

E.S.R	2	0 - 14	mm at 1 hr
-------	---	--------	------------

METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)

## Interpretation(s)

## ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

## TEST INTERPRETATION

**Increase** in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

**Decreased** in: Polycythemia vera, Sickle cell anemia

## LIMITATIONS

**False elevated** ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

**False Decreased** : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

## REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition;2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin;3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

Dr. Reena Mittal, MD  
Senior Consultant  
Hematopathologist

Dr. Sushant Chikane  
Consultant Pathologist

Page 8 Of 21



View Details



View Report

## PERFORMED AT :

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011697304





MC-2010

PATIENT NAME : AMIT ASHISH

REF. DOCTOR : SELF

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

### IMMUNOHAEMATOLOGY

#### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

#### ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP	A
METHOD : HAEMAGGLUTINATION (AUTOMATED)	
RH TYPE	POSITIVE
METHOD : HAEMAGGLUTINATION (AUTOMATED)	

#### Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

**Dr. Sushant Chikane**  
Consultant Pathologist

Page 9 Of 21



View Details



View Report

#### PERFORMED AT :

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011697304



MC-2010

**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**BIOCHEMISTRY**

**MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE**

**GLUCOSE FASTING,FLUORIDE PLASMA**

FBS (FASTING BLOOD SUGAR)	96	Normal <100 mg/dL Impaired fasting glucose:100 to 125 Diabetes mellitus: > = 126 (on more than 1 occassion) (ADA guidelines 2021)
---------------------------	----	--

METHOD : SPECTROPHOTOMETRY HEXOKINASE

**GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD**

HBA1C	5.3	Non-diabetic Adult < 5.7 % Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)
-------	-----	--

METHOD : ION- EXCHANGE HPLC

ESTIMATED AVERAGE GLUCOSE(EAG)	105.4	< 116 mg/dL
--------------------------------	-------	-------------

**GLUCOSE, POST-PRANDIAL, PLASMA**

PPBS(POST PRANDIAL BLOOD SUGAR)	131	Normal <140 mg/dL Impaired glucose tolerance:140 to 199 Diabetes mellitus : > = 200 (on more than 1 occassion) ADA guideline 2021
---------------------------------	-----	--

METHOD : SPECTROPHOTOMETRY HEXOKINASE

**LIPID PROFILE, SERUM**

CHOLESTEROL, TOTAL	173	Desirable : < 200 mg/dL Borderline : 200 - 239 High : > / = 240
--------------------	-----	---

METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - CHOLETSEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES	138	Normal: < 150 mg/dL Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500
---------------	-----	--

METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH GLYCEROL BLANK

*S.S.Wadalkar*

**Dr. Sneha Wadalkar, M.D**  
(Reg.no.MMC2012/06/1868)  
Junior Biochemist



View Details

View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**



**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HDL CHOLESTEROL 44 At Risk: < 40 mg/dL  
Desirable: > or = 60

METHOD : SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT ENZYMATIC COLORIMETRIC

CHOLESTEROL LDL **101 High** Optimal : < 100 mg/dL  
Near optimal/above optimal : 100-129  
Borderline high : 130-159  
High : 160-189  
Very high : = 190

METHOD : CALCULATED PARAMETER

NON HDL CHOLESTEROL 129 Desirable : < 130 mg/dL  
Above Desirable : 130 -159  
Borderline High : 160 - 189  
High : 190 - 219  
Very high : > / = 220

METHOD : CALCULATED PARAMETER

VERY LOW DENSITY LIPOPROTEIN 28.0 < or = 30.0 mg/dL

CHOL/HDL RATIO 3.9 Low Risk : 3.3 - 4.4  
Average Risk : 4.5 - 7.0  
Moderate Risk : 7.1 - 11.0  
High Risk : > 11.0

METHOD : CALCULATED PARAMETER

LDL/HDL RATIO 2.5 Desirable/Low Risk : 0.5 - 3.0  
Borderline/Moderate Risk : 3.1 - 6.0  
High Risk : > 6.0

METHOD : CALCULATED PARAMETER

**Interpretation(s)**

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

**Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India**

Risk Category	
Extreme risk group	A.CAD with > 1 feature of high risk group
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia

*S.S. Wadalkar*

**Dr. Sneha Wadalkar, M.D**  
**(Reg.no.MMC2012/06/1868)**  
**Junior Biochemist**



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**



MC-2010

**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors
<b>Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors</b>	
1. Age > or = 45 years in males and > or = 55 years in females	3. Current Cigarette smoking or tobacco use
2. Family history of premature ASCVD	4. High blood pressure
5. Low HDL	

**Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.**

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30 )	< 80 (Optional goal <OR = 60)	>OR = 50	>OR = 80
Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

\*After an adequate non-pharmacological intervention for at least 3 months.

**References:** Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

**LIVER FUNCTION PROFILE, SERUM**

BILIRUBIN, TOTAL	0.70	Upto 1.2	mg/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -DIAZO METHOD			
BILIRUBIN, DIRECT	0.27	< or = 0.3	mg/dL
METHOD : SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIAZOTIZATION			
BILIRUBIN, INDIRECT	0.43	0.0 - 0.9	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	7.5	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGENT BLANK, SERUM BLANK			
ALBUMIN	4.5	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING			
GLOBULIN	3.0	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.5	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	<b>62 High</b>	Upto 40	U/L
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION( P5P) - IFCC			

*S.S. Wadalkar*

**Dr. Sneha Wadalkar, M.D**  
**(Reg.no.MMC2012/06/1868)**  
**Junior Biochemist**



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**



MC-2010

**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

<b>ALANINE AMINOTRANSFERASE (ALT/SGPT)</b>	<b>117 High</b>	Upto 41	U/L
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION( P5P) - IFCC			
<b>ALKALINE PHOSPHATASE</b>	61	40 - 129	U/L
METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC			
<b>GAMMA GLUTAMYL TRANSFERASE (GGT)</b>	43	< 60	U/L
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-GLUTAMYL-CARBOXY-NITROANILIDE - IFCC			
<b>LACTATE DEHYDROGENASE</b>	203	< 232	U/L
METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC			
<b>BLOOD UREA NITROGEN (BUN), SERUM</b>			
<b>BLOOD UREA NITROGEN</b>	7	6 - 20	mg/dL
METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC			
<b>CREATININE, SERUM</b>			
<b>CREATININE</b>	<b>0.85 Low</b>	0.90 - 1.30	mg/dL
METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARDIZED			
<b>BUN/CREAT RATIO</b>			
<b>BUN/CREAT RATIO</b>	8.24	8 - 15	
METHOD : CALCULATED PARAMETER			
<b>URIC ACID, SERUM</b>			
<b>URIC ACID</b>	5.9	3.4 - 7.0	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC- URICASE			
<b>TOTAL PROTEIN, SERUM</b>			
<b>TOTAL PROTEIN</b>	7.5	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGENT BLANK, SERUM BLANK			
<b>ALBUMIN, SERUM</b>			
<b>ALBUMIN</b>	4.5	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING			
<b>GLOBULIN</b>			
<b>GLOBULIN</b>	3.0	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER			
<b>ELECTROLYTES (NA/K/CL), SERUM</b>			
<b>SODIUM, SERUM</b>	138	136 - 145	mmol/L
METHOD : ISE INDIRECT			
<b>POTASSIUM, SERUM</b>	4.50	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT			
<b>CHLORIDE, SERUM</b>	102	98 - 106	mmol/L

*S.S. Wadalkar*

**Dr. Sneha Wadalkar, M.D**  
**(Reg.no.MMC2012/06/1868)**  
**Junior Biochemist**



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**



MC-2010



**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

METHOD : ISE INDIRECT

**Interpretation(s)**

Sodium	Potassium	Chloride
<b>Decreased in:</b> CCF,cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy,adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide,carbamazepine,anti depressants (SSRI), antipsychotics.	<b>Decreased in:</b> Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	<b>Decreased in:</b> Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism,metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
<b>Increased in:</b> Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	<b>Increased in:</b> Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison' s disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole.	<b>Increased in:</b> Renal failure, nephrotic syndrome, RTA,dehydration, overtreatment with saline,hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis,hyperadrenocorticism. Drugs: acetazolamide,androgens, hydrochlorothiazide,salicylates.
<b>Interferences:</b> Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	<b>Interferences:</b> Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	<b>Interferences:</b> Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

**Interpretation(s)**

**GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

**Increased in:**Diabetes mellitus, Cushing' s syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

**Decreased in :**Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

**NOTE:** While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment,Renal Glycosuria,Glycaemic index & response to food consumed,Alimentary Hypoglycemia,Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For:**

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

*S.S.Wadalkar*

**Dr. Sneha Wadalkar, M.D**  
**(Reg.no.MMC2012/06/1868)**  
**Junior Biochemist**



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**



MC-2010



**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**HbA1c Estimation can get affected due to :**

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia,uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods,falsely increasing results.
4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

**Bilirubin** is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice.**Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

**AST** is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis,sometimes due to a viral infection,ischemia to the liver,chronic hepatitis,obstruction of bile ducts,cirrhosis.

**ALP** is a protein found in almost all body tissues.Tissues with higher amounts of ALP include the liver,bile ducts and bone.Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia,Malnutrition,Protein deficiency,Wilsons disease.

**GGT** is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas.It is also found in other tissues including intestine,spleen,heart, brain and seminal vesicles.The highest concentration is in the kidney,but the liver is considered the source of normal enzyme activity.Serum GGT has been widely used as an index of liver dysfunction.Elevated serum GGT activity can be found in diseases of the liver,biliary system and pancreas.Conditions that increase serum GGT are obstructive liver disease,high alcohol consumption and use of enzyme-inducing drugs etc.

**Total Protein** also known as total protein,is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

**Albumin** is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc

**BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

**Causes of decreased** level include Liver disease, SIADH.

**CREATININE, SERUM-Higher than normal level may be due to:**

- Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

**Lower than normal level may be due to:**

- Myasthenia Gravis, Muscuophy

**URIC ACID, SERUM-Causes of Increased levels:-**Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis

**TOTAL PROTEIN, SERUM-is** a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

**Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease.

**Lower-than-normal levels may be due to:** Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

*S.S.Wadalkar*

**Dr. Sneha Wadalkar, M.D**  
(Reg.no.MMC2012/06/1868)  
**Junior Biochemist**



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**



MC-2010

**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**CLINICAL PATH - URINALYSIS**

**MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE**

**PHYSICAL EXAMINATION, URINE**

COLOR PALE YELLOW  
 APPEARANCE CLEAR

**CHEMICAL EXAMINATION, URINE**

PH	6.0	5.00 - 7.50
SPECIFIC GRAVITY	1.015	1.010 - 1.030
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NOT DETECTED	
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

**MICROSCOPIC EXAMINATION, URINE**

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	1-2	0-5	/HPF
EPITHELIAL CELLS	0-1	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	

METHOD : URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

**Interpretation(s)**

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment

*S.S. Wadalkar*

**Dr. Sneha Wadalkar, M.D**  
 (Reg.no.MMC2012/06/1868)  
 Junior Biochemist



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
 Mumbai, 400062  
 MAHARASHTRA, INDIA  
 Tel : 9111591115, Fax :  
 CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**





MC-2010

**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infection when present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

*S.S. Wadalkar*

**Dr. Sneha Wadalkar, M.D**  
(Reg.no.MMC2012/06/1868)  
Junior Biochemist



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**



MC-2010

**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**CLINICAL PATH - STOOL ANALYSIS**

**MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE**

**PHYSICAL EXAMINATION,STOOL**

COLOUR	BROWN	
CONSISTENCY	SEMI FORMED	
MUCUS	NOT DETECTED	NOT DETECTED
VISIBLE BLOOD	ABSENT	ABSENT
ADULT PARASITE	NOT DETECTED	

METHOD : MICROSCOPIC EXAMINATION

**CHEMICAL EXAMINATION,STOOL**

STOOL PH	6.0	
OCCULT BLOOD	NOT DETECTED	NOT DETECTED

METHOD : MODIFIED GUAIAC METHOD

**MICROSCOPIC EXAMINATION,STOOL**

PUS CELLS	0-1		/hpf
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
CYSTS	NOT DETECTED	NOT DETECTED	
OVA	NOT DETECTED		
LARVAE	NOT DETECTED	NOT DETECTED	
TROPHOZOITES	NOT DETECTED	NOT DETECTED	
FAT	ABSENT		
CHARCOT LEYDEN CRYSTALS	ABSENT		

**Interpretation(s)**

Stool routine analysis is only a screening test for disorders of gastrointestinal tract like infection, malabsorption, etc.The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection

**Dr. Ekta Patil,MD**  
(Reg.No. MMC2008/04/1142)  
Senior Microbiologist



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011697304





MC-2010

**PATIENT NAME : AMIT ASHISH**

**REF. DOCTOR : SELF**

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

<b>Test Report Status</b>	<b>Final</b>	<b>Results</b>	<b>Biological Reference Interval</b>	<b>Units</b>
---------------------------	--------------	----------------	--------------------------------------	--------------

**SPECIALISED CHEMISTRY - HORMONE**

**MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE**

**THYROID PANEL, SERUM**

T3	127.0	80.0 - 200.0	ng/dL
METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY			
T4	7.32	5.10 - 14.10	µg/dL
METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY			
TSH (ULTRASENSITIVE)	<b>4.750 High</b>	0.270 - 4.200	µIU/mL
METHOD : SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY			

**Interpretation(s)**

**Triiodothyronine T3 , Thyroxine T4, and Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1) Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism

*S.S. Wadalkar*

**Dr. Sneha Wadalkar, M.D**  
(Reg.no.MMC2012/06/1868)  
Junior Biochemist



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956



**Patient Ref. No. 2000011697304**



MC-2010

PATIENT NAME : AMIT ASHISH

REF. DOCTOR : SELF

ACCESSION NO : <b>0002WC059597</b>	AGE/SEX : 36 Years Male
PATIENT ID : AMITM1204862:	DRAWN : 30/03/2023 08:18:58
CLIENT PATIENT ID:	RECEIVED : 30/03/2023 08:20:58
ABHA NO :	REPORTED : 31/03/2023 13:58:25

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011.

**NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.**

**\*\*End Of Report\*\***Please visit [www.srlworld.com](http://www.srlworld.com) for related Test Information for this accession**CONDITIONS OF LABORATORY TESTING & REPORTING**

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type
  - iv. Discrepancy between identification on specimen container label and test requisition form
5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

**SRL Limited**Fortis Hospital, Sector 62, Phase VIII,  
Mohali 160062

**Dr. Sneha Wadalkar, M.D**  
(Reg.no.MMC2012/06/1868)  
Junior Biochemist

Page 21 Of 21



View Details



View Report

**PERFORMED AT :**

SRL Ltd  
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)  
Mumbai, 400062  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax :  
CIN - U74899PB1995PLC045956

**Patient Ref. No. 2000011697304**